Novozymes A/S

Novozymes A/S

NVZMY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$31.01B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Novozymes A/SNovozymes A/S40.91.44%-2%7.30.3

Earnings Call Q3 2026

November 5, 2026 - AI Summary

Strong topline + margin delivered; confident full-year guidance - Organic sales +7% in the first 9 months of 2026 (including ~1pp negative from exiting certain countries). - Growth drivers: ~2pp pricing and ~1pp sales synergies. - Adjusted EBITDA margin 37.9% (up +60 bps YoY), and 38.3% in Q3 (up +120 bps YoY), driven by sales leverage, productivity and pricing. - Q4 outlook: high-single-digit organic growth expected. - Full-year outlook reiterated: 7%–8% organic sales growth, ~1pp synergies, ~1.5pp pricing, and ~1pp negative from country exits.
Healthy divisional performance overall; key risk is Human Health (North America) - Food & Health Biosolutions: +9% organic (first 9 months), 37% EBITDA margin (+100 bps YoY). Pricing/synergies positive; country exits ~2pp negative. - Food & Beverages: standout +12% organic (9 months) and +14% in Q3, supported by innovation adoption and customer penetration (demand for healthier/cleaner-label products, probiotics, higher protein, lower sugar, etc.). - Human Health: flat organically in first 9 months; -8% in Q3 due to US dietary supplement softness. - Specific headwind: changing US consumer behavior + reduced buying power; customers de-stocked, adding pressure vs expectations. - Management view: issue is isolated to North America and actions/reformulation pipeline should support recovery in 2H 2027 (or earlier if market rebounds).
AET (Animal, Agricultural, Energy, Tech) solid; growth acceleration in Q4 partly explained - Planetary Health Biosolutions: +6% organic (9 months), 38.6% EBITDA margin (+90 bps), with slight currency headwind; Q3 +4%. - AET division growth mix drivers: - Animal: benefited from probiotics+enzymes strategy; underlying demand strong despite inventory effects earlier in year. - Energy: double-digit growth in first 9 months (momentum in 2nd-gen ethanol; decoupling from fossil fuels supports demand). - Tech: declined on order timing and softer end markets; Plant declined due to weak US farm economics. - Management explicitly expects Q4 organic growth to be high single digits, and notes acceleration vs Q3 (also referencing softer comparable effects).

Exclusive for Stockcircle Pro members

Sign upSign Up
$-2.20

Current Fair Value

103.3% downside

Overvalued by 103.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$31.01 Billion
Enterprise Value$33.44 Billion
Annual dividend$0.16
Dividend yield1.44%
Earnings per Share$1.35
Beta0.62
Outstanding Shares469,750,000

Return

Return on Equity-1.81%ROE
Return on Assets-1.21%
Return on Invested Capital6.50%

Valuation & Multiples

P/E Ratio40.92P/E Ratio
PEG111.42PEG
Price to Sales7.33Price to Sales
Price to Book Ratio2.87Price to Book Ratio
Enterprise Value to Revenue7.62
Enterprise Value to EBIT33.55
Enterprise Value to Net Income-165
Total Debt to Enterprise0.09
Debt to Equity0.26Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
$0.48
Est. $0.74
Revenue
$1.28 B
Est. $1.28 B

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
$0.65
Consensus analyst estimate
Revenue Estimate
$1.24 B
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.00%▼ 0.00%
Total Invested$1.38M▼ 6.09%
Investors Holding6▼ 3.00%

About Novozymes A/S

11,098 employees
CEO: Ester Baiget

Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends ...